URINARY LEUKOTRIENE-E4 LEVELS DURING EARLY AND LATE ASTHMATIC RESPONSES

被引:169
作者
MANNING, PJ
ROKACH, J
MALO, JL
ETHIER, D
CARTIER, A
GIRARD, Y
CHARLESON, S
OBYRNE, PM
机构
[1] MCMASTER UNIV, HLTH SCI CTR, DEPT MED, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA
[2] HOP SACRE COEUR, MONTREAL H4J 1C5, QUEBEC, CANADA
[3] MERCK FROSST CTR THERAPEUT RES, KIRKLAND, QUEBEC, CANADA
关键词
D O I
10.1016/S0091-6749(05)80068-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The sulphidopeptide leukotrienes C4 and D4 (LTC4, LTD4) are protent bronchoconstrictor mediators, released from human lung fragments after challenge with specific allergens in vitro. The purpose of this study was to measure urinary LTE4 (metabolite of LTC4 and LTD4) in subjects undergoing inhalation challenges with allergens or occupational sensitizing agents in the laboratory. Eighteen subjects with previously documented isolated early asthmatic responses (EARs), isolated late asthmatic responses (LARs), or dual (both early and late) asthmatic responses were studied. Urinary LTE4 levels increased in subjects who developed either isolated EARs (mean fall in FEV1, 27.98%) or early responses preceding LARs (mean fall in FEV1, 15.01%). The baseline levels of LTE4 were 150.26 (SEM, 49.5) pg/mg of creatinine in the isolated responders and 66.60 (SEM, 13.5) pg/mg of creatinine in the dual responders. These levels increased to 1816 (SEM, 606.1) pg/mg of creatinine (p=0.041) and 174.80 (SEM, 40.1) pg/mg of creatinine (p=0.025), respectively, after the EAR. The degree of maximal bronchoconstriction during the EAR correlated with the levels of LTE4 (r=0.68; p=0.001). No significant increase in urinary LTE4 levels occurred during the LAR. These results suggest that the LTE4 precursors, LTC4 and LTD4, are important bronchoconstrictor mediators causing EARs after allergen inhalation. © 1990 Mosby-Year Book, Inc.
引用
收藏
页码:211 / 220
页数:10
相关论文
共 37 条
[11]   ALLERGEN CHALLENGE OF LUNG-TISSUE FROM ASTHMATICS ELICITS BRONCHIAL CONTRACTION THAT CORRELATES WITH THE RELEASE OF LEUKOTRIENE-C4, LEUKOTRIENE-D4, AND LEUKOTRIENE-E4 [J].
DAHLEN, SE ;
HANSSON, G ;
HEDQVIST, P ;
BJORCK, T ;
GRANSTROM, E ;
DAHLEN, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (06) :1712-1716
[12]   SYNTHESIS OF BETA-OXIDATION PRODUCTS AS POTENTIAL LEUKOTRIENE METABOLITES AND THEIR DETECTION IN BILE OF ANESTHETIZED RAT [J].
DELORME, D ;
FOSTER, A ;
GIRARD, Y ;
ROKACH, J .
PROSTAGLANDINS, 1988, 36 (03) :291-302
[13]  
DELUCA S, 1988, EUR RESPIR J, V1, P540
[14]  
DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373
[15]  
DENZLINGER C, 1986, J BIOL CHEM, V261, P5601
[16]   LEUKOTRIENES AND AIRWAY RESPONSES [J].
DRAZEN, JM ;
AUSTEN, KF .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (04) :985-998
[17]   EVIDENCE OF INVIVO W-OXIDATION OF PEPTIDE LEUKOTRIENES IN THE RAT - BILIARY-EXCRETION OF 20-CO2H N-ACETYL LTE4 [J].
FOSTER, A ;
FITZSIMMONS, B ;
ROKACH, J ;
LETTS, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 148 (03) :1237-1245
[18]   METABOLISM AND EXCRETION OF PEPTIDE LEUKOTRIENES IN THE ANESTHETIZED RAT [J].
FOSTER, A ;
FITZSIMMONS, B ;
ROKACH, J ;
LETTS, LG .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 921 (03) :486-493
[19]  
FOSTER A, 1988, J IMMUNOL, V141, P3544
[20]  
HAYES EC, 1983, J IMMUNOL, V131, P429